Middletown Life

Author: Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

April 28, 2026
Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework

April 28, 2026
Fosun Pharma Announces 2025 Annual Results

March 24, 2026
Chinese medical team enables 30 type 1 diabetes patients to discontinue insulin through integrative medicine

March 12, 2026
Fosun Pharma’s Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

December 9, 2025